

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (original) A calcium or a magnesium salt of (2*S*)-2-ethoxy-3-(4-{2-[hexyl(2-phenylethyl)-amino]-2-oxoethoxy}phenyl)propanoic acid.
2. (original) A calcium salt of (2*S*)-2-ethoxy-3-(4-{2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy}phenyl)propanoic acid.
3. (currently amended) A salt as claimed in either claim 1 or claim 2 which ~~may be~~ is a solvate, a hydrate, a mixed solvate/hydrate, an anhydrate or an anhydrous.
4. (currently amended) A salt as claimed in ~~any one of claims 1-3~~ either claim 1 or claim 2 in crystalline or partially crystalline form.
5. (currently amended) A salt as claimed in ~~any one of claims 1-4~~ either claim 1 or claim 2 either in the form of a mixed salt together with a pharmaceutically inactive counterion.
6. (currently amended) A salt as claimed in ~~any one of claims 2-4~~ either claim 1 or claim 2 wherein the pharmaceutically inactive counterion is [CaCl]⁺.
7. (currently amended) A pharmaceutical formulation comprising a compound according to ~~any one of claims 1 to 6~~ either claim 1 or claim 2 in admixture with pharmaceutically acceptable adjuvants, diluents and/or carriers.
8. (currently amended) A method of treating or preventing lipid disorders (dyslipidemia) whether or not associated with insulin resistance comprising the administration of a compound according to ~~any one of claims 1 to 6~~ either claim 1 or claim 2 to a mammal in need thereof.

9. (cancelled)

10. (currently amended) A method of treating or preventing type 2 diabetes comprising ~~the administration of~~ administering an effective amount of a compound of formula I according to ~~any one of claims 1 to 6~~ either claim 1 or claim 2 to a mammal in need thereof.

11. (currently amended) A pharmaceutical composition comprising a compound according to ~~any one of claims 1 to 6~~ either claim 1 or claim 2 combined with another therapeutic agent that is useful in the treatment of disorders associated with the development and progress of atherosclerosis such as hypertension, hyperlipidaemias, dyslipidaemias, diabetes and obesity.

12. (new) A pharmaceutical formulation comprising a compound according to claim 5 with pharmaceutically acceptable adjuvants, diluents and/or carriers.